Current Status of Research on Anti-osteoporotic Drug Treatment and Compliance in Patients with Osteoporotic Fractures

Abstract

Osteoporotic Fracture (OPF), also known as fragility fracture, is a low-energy, non-violent fracture that commonly occurs in the elderly. Such fractures mostly occur in the thoracolumbar vertebral body, hip, distal radius and other parts, and are the main factors that cause osteoporosis patients to be hospitalized for diagnosis and treatment. Secondary fractures are prone to occur after fractures, and anti-osteoporotic treatment can effectively prevent further fractures in patients with osteoporotic fractures. Due to factors such as patients and their families’ insufficient understanding of the necessity of anti-osteoporosis drug treatment after fragility fractures, insufficient awareness of the risk of re-fracture, lack of follow-up management of drug compliance after treatment, and untimely monitoring of anti-osteoporosis efficacy, etc. The treatment initiation rate and medication compliance of anti-osteoporosis drugs in patients with osteoporotic fractures are low. This article systematically reviews the incidence and disease burden of osteoporotic fractures, the understanding of diagnosis, treatment and management of osteoporotic fractures, the status of anti-osteoporotic drug treatment and compliance, and efficacy monitoring of patients after osteoporotic fractures. Provide a reference for establishing effective medication compliance management for OPF patients.